Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation

Roberto Fogari, Amedeo Mugellini, Annalisa Zoppi, Paola Preti, Maurizio Destro, Pierangelo Lazzari, Giuseppe Derosa

Research output: Contribution to journalArticlepeer-review

Abstract

This study evaluated the effect of telmisartan, ramipril, and amlodipine on atrial fibrillation (AF) recurrence and severity in hypertensive patients with metabolic syndrome. A total of 391 hypertensive outpatients with metabolic syndrome, in sinus rhythm but with at least 2 episodes of AF in the previous 6 months were randomized to telmisartan, ramipril, or amlodipine for 1 year. At the first AF, ventricular rate (VR) and plasma cardiac troponin I (TnI) were evaluated. P-wave dispersion (PWD) and procollagen type I carboxy-terminal peptide (PIP) were evaluated before and after 12 months of treatment. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were similarly and significantly reduced by all treatments (P

Original languageEnglish
Pages (from-to)34-43
Number of pages10
JournalJournal of Cardiovascular Pharmacology and Therapeutics
Volume17
Issue number1
DOIs
Publication statusPublished - Mar 2012

Keywords

  • amlodipine
  • atrial fibrillation
  • hypertension
  • ramipril
  • telmisartan

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation'. Together they form a unique fingerprint.

Cite this